🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 811292200 (prev. 811292101 )
- Market Cap
- Micro Cap
- IPO
- 5/2/2014 · $10.00/share
Business: Scynexis, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Scynexis is developing a lead product candidate as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Notes: July 16, 2020 -- SCYNEXIS, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”), which will, effective at 12:01 am on Friday, July 17, 2020, (a) implement a 1-for-10 reverse stock split of the SCYNEXIS’s common stock and (b) decrease the number of authorized shares of SCYNEXIS’s common stock from 250,000,000 shares to 100,000,000 shares.
SCYNEXIS’s common stock will begin trading on the Nasdaq Global Market on a split-adjusted basis when the market opens on July 17, 2020. The new CUSIP number for SCYNEXIS’s common stock following the reverse stock split is 811292200.
Company Contact
- CEO
- Marco Taglietti
- CFO
-
Ivor Macleod
- Headquarters
- 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302
- Phone
- 201-884-5485
- Fax
- 919-544-8697
- Investor Relations
- Irina Koffler, LifeSci Advisors · 646-970-4681 · ikoffler@lifesciadvisors.com